11
|
Toomey S, Eustace AJ, Pritzker LB, Pritzker KPH, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT. RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Natl Cancer Inst 2016; 108:djw111. [PMID: 27377904 DOI: 10.1093/jnci/djw111] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 03/09/2016] [Indexed: 11/12/2022] Open
Affiliation(s)
- Sinead Toomey
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Alex J Eustace
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).
| | - Laura B Pritzker
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Ken P H Pritzker
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Joanna Fay
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Anthony O'Grady
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Robert Cummins
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Liam Grogan
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - John Kennedy
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Darran O'Connor
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Leonie Young
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Elaine W Kay
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Norma O'Donovan
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - William M Gallagher
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Roshni Kalachand
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - John Crown
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| | - Bryan T Hennessy
- Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH)
| |
Collapse
|